{"slug":"tb-500-nerve-damage","verification":{"valid":true,"entries":2,"head":"fcda2d0f877d91e96a2810745b2b782210a22e16351c3662a55ef49ad062efc1"},"energy":{"passes":2,"tokens_in":38653,"tokens_out":2723,"tokens_total":41376,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"fcda2d0f877d91e96a2810745b2b782210a22e16351c3662a55ef49ad062efc1"},"provenance":[{"ts":"2026-06-29T23:34:58.429Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: TB 500 for Nerve Damage\nSlug: tb-500-nerve-damage\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tb-500\",\"name\":\"TB-500\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tb-500\",\"name\":\"TB-500\",\"section_title\":\"Why TB-500 might help you\",\"layer\":\"inflammation clearance / repair-cell migration\",\"steps\":[\"**What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\",\"**What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\",\"**Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"],\"prose\":\"1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stac","response":"{\n  \"slug\": \"tb-500-nerve-damage\",\n  \"title\": \"TB-500 for Nerve Damage: Evidence-Graded Review\",\n  \"body\": \"## What's breaking down\\n\\nNerve damage involves layers of degeneration where repair pathways stall. Axons may fail to regrow due to disrupted actin cytoskeleton and poor cell migration to the injury site. Inflammation can persist instead of clearing, blocking new blood vessel formation and tissue rebuilding. In models of diabetic neuropathy or spinal cord injury, conduction velocity drops and functional recovery lags because repair cells do not reach the damage effectively. TB-500 targets these repair layers rather than suppressing symptoms.\\n\\n## Why TB-500 might help you\\n\\n1. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\\n2. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\\n3. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus — TB-500 targets inflammation clearance / repair-cell migration.\\n\\n## What the evidence actually shows\\n\\nNo completed human interventional trials test TB-500 or thymosin beta-4 specifically for nerve damage or neuropathy (preclinical tier from scoping reviews). A 2026 scoping review of 80 studies found the evidence base weighted toward in vitro and mixed designs, with human data limited to ocular and wound contexts and no direct TB-500 nerve studies. Animal studies provide the primary data. In a 2012 mouse model of diabetic peripheral neuropathy, thymosin beta-4 treatment improved sciatic nerve conduction velocity and neurovascular function compared to controls (preclinical tier). In a 2014 rat spinal cord injury model, thymosin beta-4 given 30 minutes to 5 days post-injury increased surviving neurons and oligodendrocyt","tokens_in":38653,"tokens_out":2723,"cost":0,"prev":"genesis","hash":"af6707540c8cec3d5619ea257f48f56b26c8dee54795f17794743b8b783c8ac6"},{"ts":"2026-07-17T02:42:16.594Z","model":"owner","action":"voxel_divide","prompt":"","input":"tb-500-nerve-damage","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"af6707540c8cec3d5619ea257f48f56b26c8dee54795f17794743b8b783c8ac6","hash":"fcda2d0f877d91e96a2810745b2b782210a22e16351c3662a55ef49ad062efc1"}]}